$0.04
Vaxxinity is a biotechnology business based in the US. Vaxxinity shares (VAXX) are listed on the PINK and all prices are listed in US Dollars. Vaxxinity employs 57 staff and has a market cap (total outstanding shares value) of 0.00.
Our top picks for where to buy Vaxxinity stock
How to buy Vaxxinity stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – VAXX. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Vaxxinity stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Vaxxinity stock price (PINK: VAXX)
Use our graph to track the performance of VAXX stocks over time.Vaxxinity shares at a glance
Latest market close | $0.00 |
---|---|
52-week range | $0.00 - $2.16 |
50-day moving average | $0.14 |
200-day moving average | $0.46 |
Wall St. target price | $15.00 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-0.45 |
Vaxxinity price performance over time
Historical closes compared with the close of $0.001 from 2024-09-05
1 week (2024-08-30) | 0.001 |
---|---|
1 month (2024-08-07) | -95.00% |
3 months (2024-06-07) | -98.95% |
6 months (2024-03-07) | -99.87% |
1 year (2023-09-07) | -99.94% |
---|---|
2 years (2022-09-07) | -99.95% |
3 years (2021-09-03) | N/A |
5 years (2019-09-03) | N/A |
Vaxxinity financials
Gross profit TTM | $-1,871,000 |
---|---|
Return on assets TTM | -48.34% |
Return on equity TTM | -150.65% |
Profit margin | 0% |
Book value | $0.11 |
Market Capitalization | $126,785 |
TTM: trailing 12 months
Vaxxinity share dividends
We're not expecting Vaxxinity to pay a dividend over the next 12 months.
You may also wish to consider:
- Pfizer (PFE.US) (5.79% forward annual dividend yield)
- AstraZeneca PLC ADR (AZN.US) (1.69% forward annual dividend yield)
Vaxxinity share price volatility
Over the last 12 months, Vaxxinity's shares have ranged in value from as little as $0 up to $2.16. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (PINK average) beta is 1, while Vaxxinity's is 3.228. This would suggest that Vaxxinity's shares are significantly more volatile than the average for this exchange and represent a higher risk.
To put Vaxxinity's beta into context you can compare it against those of similar companies.
- Moderna (MRNA.US): 1.662
- Pfizer (PFE.US): 0.633
- AstraZeneca PLC ADR (AZN.US): 0.148
Vaxxinity overview
Vaxxinity, Inc. , a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer's disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial. The company was incorporated in 2021 and is headquartered in Merritt Island, Florida. .
Frequently asked questions
What percentage of Vaxxinity is owned by insiders or institutions?Currently 50.707% of Vaxxinity shares are held by insiders and 0.321% by institutions. How many people work for Vaxxinity?
Latest data suggests 57 work at Vaxxinity. When does the fiscal year end for Vaxxinity?
Vaxxinity's fiscal year ends in December. Where is Vaxxinity based?
Vaxxinity's address is: 505 Odyssey Way, Merritt Island, FL, United States, 32953 What is Vaxxinity's ISIN number?
Vaxxinity's international securities identification number is: US92244V1044
More guides on Finder
-
Best paper trading platforms to practice trading with fake money [2024]
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
-
7 best day trading platforms of 2024
These are the best day trading platforms, according to Finder’s comprehensive analysis.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
Trading for beginners: 11 best trading platforms to get started
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
-
5 best international stock brokers to invest in foreign assets
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
-
9 best discount brokers of 2024 for low-cost trading and investing
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
-
10 best stock apps of 2024 to elevate your mobile trading
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
-
10 best brokerage accounts for buying stocks, options and more in 2024
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
5 best ETFs for 2024
Check out the best-performing ETFs so far in 2024.
Ask a question